Rhodiola Rosea (Rhodiola rosea L.)

Table of Contents

Overview -- The Golden Root Adaptogen

Rhodiola rosea, widely known as golden root, roseroot, Arctic root, and king's crown, is one of the most extensively studied adaptogenic herbs in the world. This remarkable perennial succulent thrives in some of the harshest environments on Earth -- from the frigid Arctic tundra of Siberia to the windswept alpine meadows of Scandinavia, the mountainous regions of Central Asia, and the rocky coastal cliffs of northern Europe. Its ability to survive and flourish under extreme conditions of cold, drought, and ultraviolet radiation has long fascinated botanists and herbalists alike, and many traditional healing systems viewed this environmental resilience as a sign that the plant could impart similar fortitude to those who consumed it.

Classified within the family Crassulaceae, Rhodiola rosea has been used for centuries across diverse cultures to combat fatigue, enhance mental clarity, improve physical stamina, and bolster the body's resistance to environmental and psychological stress. The herb earned its most evocative common name -- golden root -- from the distinctive golden-yellow color of its thick, scaly rhizome when freshly cut. When sliced open, the root also releases a fragrance reminiscent of rose petals, which gives the plant its species name rosea.

In modern phytomedicine, Rhodiola rosea is classified as an adaptogen -- a natural substance that helps the body adapt to physical, chemical, and biological stressors while maintaining homeostasis. This concept, first formalized by Soviet pharmacologist Dr. Nikolai Lazarev in 1947 and later refined by Dr. Israel Brekhman, defines adaptogens as agents that produce a nonspecific increase in resistance to a broad spectrum of stressors without disturbing normal biological functions. Rhodiola rosea meets all three classical criteria for an adaptogen: it is nontoxic at normal therapeutic doses, it produces a nonspecific defensive response to stress, and it exerts a normalizing influence on physiology regardless of the direction of the stressor.

The European Medicines Agency (EMA) formally recognized Rhodiola rosea in 2011 with an official herbal monograph approving its traditional use as an adaptogen for the temporary relief of stress-related symptoms, including fatigue, exhaustion, and a general sensation of weakness. Today, hundreds of scientific studies have investigated its pharmacological properties, and clinical trials continue to reveal the breadth and depth of its therapeutic potential across domains ranging from cognitive performance and mood regulation to cardiovascular protection and immune function.

History and Traditional Use

The medicinal history of Rhodiola rosea stretches back more than two thousand years, making it one of the oldest documented healing herbs in Eurasian medicine. The earliest known written reference to the plant appears in the works of the Greek physician Pedanius Dioscorides, who described a plant called rodia riza in his landmark pharmacological text De Materia Medica around 77 CE. Dioscorides noted the plant's medicinal applications and documented its use by the peoples of the ancient Mediterranean world, establishing Rhodiola as a recognized therapeutic agent in the classical Western tradition.

Perhaps the most legendary chapter in Rhodiola's history involves the Norse Vikings, who are said to have used the herb extensively to enhance their physical strength, endurance, and mental fortitude during their far-reaching voyages and military campaigns from the 8th through 11th centuries. According to historical accounts, the Vikings who settled along the rocky coasts of the British Isles -- particularly in northern Scotland, the Orkney Islands, and Iceland -- harvested Rhodiola rosea from coastal cliffs and prepared it as a tea, which they consumed in large quantities before engaging in combat or undertaking long sea voyages. The herb was believed to increase energy, stamina, and courage, qualities essential for warriors and seafarers navigating the treacherous North Atlantic.

In Siberian folk medicine, Rhodiola rosea occupies a place of deep cultural reverence. Known throughout Siberia as zolotoy koren (golden root), the herb has been a cornerstone of traditional healing practices for centuries. Siberian villagers have long believed that drinking Rhodiola tea promotes longevity and protects against the debilitating effects of their region's extreme climate. In a particularly charming tradition, bouquets of Rhodiola root were given to newlywed couples as a wedding gift to promote fertility, health, and the birth of healthy children. The root was also one of the few natural sources of vitamin C available during the long Siberian winters, and it played a critical role in preventing scurvy among isolated communities.

In Traditional Chinese Medicine (TCM), Rhodiola -- known as hong jing tian -- has been used for centuries to replenish qi (vital energy), invigorate blood circulation, and treat conditions associated with oxygen deprivation at high altitudes. Tibetan physicians prescribed Rhodiola preparations for altitude sickness, lung ailments, and general debility, and the herb remains an important component of the Tibetan pharmacopoeia to this day. Chinese emperors reportedly sent expeditions to Siberia specifically to procure golden root for their royal physicians.

The modern scientific study of Rhodiola rosea began in earnest during the Cold War era, when the Soviet Union launched extensive classified research programs to identify natural substances that could enhance the physical and mental performance of soldiers, athletes, cosmonauts, and political leaders. Beginning in the 1960s, Soviet scientists conducted hundreds of studies on Rhodiola, much of which remained classified or published only in Russian and Scandinavian journals for decades. This research was part of a broader Soviet effort to develop adaptogens as performance-enhancing agents, and Rhodiola quickly emerged as one of the most promising candidates. Soviet Olympic athletes and military personnel were among the first to use standardized Rhodiola extracts, contributing to the herb's reputation as a powerful ergogenic and cognitive enhancer.

Botanical Description

Rhodiola rosea is a perennial flowering plant belonging to the family Crassulaceae, which also includes the well-known stonecrops (Sedum species) and houseleeks (Sempervivum species). The genus Rhodiola comprises approximately 90 species distributed primarily across the cold and mountainous regions of the Northern Hemisphere, but R. rosea is by far the most extensively studied and commercially important member of the group. The species was formally named by the Swedish botanist Carl Linnaeus in 1725, who recognized its distinctive botanical characteristics and documented its distribution across Scandinavia.

The plant typically grows to a height of 5 to 40 centimeters (2 to 16 inches), forming compact, succulent clusters that emerge from a thick, fleshy rootstock covered in papery, scale-like leaves. The aerial stems are erect and unbranched, bearing alternate, oblong to spatulate leaves that are fleshy and glaucous (bluish-green), with smooth margins or slight serrations toward the tips. The succulent nature of the leaves and stems reflects the plant's membership in the Crassulaceae family and its adaptation to water-scarce environments through the storage of moisture in its tissues.

Rhodiola rosea is a dioecious species, meaning that individual plants are either exclusively male or exclusively female. This is a relatively unusual trait among flowering plants and has important implications for both wild populations and cultivation efforts. The flowers are small and star-shaped, typically arranged in dense, terminal clusters called cymes. They consist of four sepals and four petals, with petals ranging in color from bright yellow to greenish-yellow, sometimes tipped with red. Male flowers contain prominent stamens with conspicuous yellow anthers, while female flowers develop into distinctive reddish-orange seed follicles. Flowering occurs in summer, typically from June through August depending on latitude and altitude.

The most pharmacologically important part of the plant is the rhizome and root system. The rhizome is thick, cylindrical, and dense, with a golden to bronze outer surface and a distinctly yellow cross-section when cut. The freshly cut rhizome releases a characteristic rose-like fragrance -- the aromatic property that inspired Linnaeus's species designation rosea. The rhizome serves as the primary reservoir for the plant's bioactive compounds, including rosavins, salidroside, and numerous other phenolic and terpenoid constituents. Rhodiola rosea grows naturally in wild Arctic and subarctic regions of Europe, Asia, and North America, including Scandinavia, Iceland, the British Isles (particularly Scotland), the Alps, the Carpathians, the Altai Mountains, and across Siberia. It colonizes rocky substrates, sea cliffs, mountain ledges, and alpine meadows at elevations up to 2,280 meters (7,500 feet), demonstrating remarkable tolerance for extreme cold, intense ultraviolet radiation, and nutrient-poor soils.

Active Compounds

The therapeutic efficacy of Rhodiola rosea is attributed to a complex matrix of bioactive phytochemicals concentrated primarily in the root and rhizome. Extensive phytochemical analysis has identified over 140 distinct compounds in the plant, but the pharmacological activity is dominated by two major classes of phenolic compounds: phenylpropanoids (the rosavins) and phenylethanoids (salidroside and tyrosol). These compounds work both independently and synergistically to produce the herb's wide-ranging adaptogenic, neuroprotective, and anti-fatigue effects.

The rosavins -- a collective term for three closely related phenylpropanoid glycosides called rosavin, rosarin, and rosin -- are considered the signature biomarker compounds of Rhodiola rosea. These molecules are essentially unique to R. rosea; other Rhodiola species either lack rosavins entirely or contain them only in trace amounts. Pharmacological studies have demonstrated that rosavin possesses a variety of biological activities, including antioxidant, lipid-lowering, analgesic, antiradiation, antitumor, and immunomodulatory effects. Interestingly, research has shown that rosavin is more pharmacologically active at higher concentrations, while salidroside is more effective at lower concentrations, suggesting complementary dose-response profiles that may enhance the overall therapeutic efficacy of whole-plant extracts.

Salidroside (also known as rhodioloside) is a glucoside of tyrosol and is considered the other primary bioactive constituent of Rhodiola rosea. Unlike the rosavins, salidroside is found in multiple Rhodiola species as well as in some other plant genera. Salidroside has been the subject of extensive pharmacological research and has demonstrated potent antioxidant, anti-inflammatory, neuroprotective, anti-apoptotic, anti-cancer, and cardioprotective properties. At the molecular level, salidroside modulates key signaling pathways including the Nrf2/HO-1 antioxidant pathway, the NF-kB inflammatory cascade, and the PI3K/AKT survival pathway, establishing it as a pleiotropic bioactive compound with broad therapeutic potential.

Tyrosol, the aglycone of salidroside, contributes additional antioxidant and anti-inflammatory effects. Other notable bioactive constituents include rhodioflavonoside (a unique flavonoid glycoside), rhodiolin, various proanthocyanidins and flavonoids (including catechins, kaempferol, and herbacetin derivatives), organic acids (gallic acid, caffeic acid, chlorogenic acid), and a range of monoterpenes (rosiridol, rosaridin) and triterpenes (daucosterol, beta-sitosterol). This rich phytochemical diversity means that whole-plant extracts likely exert pharmacological effects through multiple simultaneous mechanisms -- a phenomenon sometimes described as the "entourage effect" in herbal medicine. Standardized Rhodiola extracts are typically calibrated to contain a minimum of 3% rosavins and 1% salidroside, reflecting the naturally occurring 3:1 ratio of these compounds in high-quality root material.

Adaptogenic Properties and HPA Axis Regulation

The adaptogenic properties of Rhodiola rosea -- its ability to increase the body's nonspecific resistance to a wide range of stressors -- represent the most thoroughly documented and clinically validated aspect of the herb's pharmacology. The concept of adaptogens, first articulated by Soviet scientist Dr. Nikolai Lazarev in 1947 and subsequently developed by Dr. Israel Brekhman in the 1960s, describes natural substances that help the organism cope with stress by normalizing physiological functions regardless of the nature or direction of the stressor. Rhodiola rosea has consistently demonstrated these properties across decades of preclinical and clinical research, establishing it as one of the most well-validated adaptogens in the scientific literature.

At the core of Rhodiola's adaptogenic mechanism is its modulation of the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress-response system. When the brain perceives a threat or stressor, the hypothalamus releases corticotropin-releasing hormone (CRH), which signals the anterior pituitary gland to secrete adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal cortex to produce the stress hormone cortisol. While this cascade is essential for short-term survival responses, chronic or excessive activation of the HPA axis leads to sustained cortisol elevation, which is associated with a wide array of detrimental health consequences including immune suppression, metabolic dysfunction, cognitive impairment, mood disorders, and accelerated aging.

Research has demonstrated that salidroside, the primary bioactive phenylethanoid in Rhodiola rosea, exerts its adaptogenic effects by reducing c-Fos expression in the paraventricular nucleus (PVN) of the hypothalamus -- a neuronal activation marker directly associated with CRH secretion. By dampening hypothalamic activation at the earliest stage of the stress cascade, Rhodiola effectively reduces the magnitude of the entire downstream HPA axis response without abolishing it entirely. This is a critical distinction: adaptogens do not block the stress response (which would be dangerous) but rather modulate it, ensuring that the body responds proportionally to the actual threat level.

Animal studies have provided compelling evidence for this mechanism. In a landmark study, rabbits treated with Rhodiola rosea and schisandra extract showed suppressed increases in phosphorylated stress-activated protein kinase (p-SAPK/p-JNK), nitric oxide (NO), and cortisol following immobilization stress. While the placebo group exhibited 200-300% increases in these stress markers, the adaptogen-treated animals maintained levels that were practically unchanged from baseline. Additionally, Rhodiola rosea has been shown to influence the activity of key stress-responsive molecular mediators including heat shock proteins (Hsp70), cortisol, and neuropeptide Y, further demonstrating its capacity to modulate the stress response at multiple molecular levels simultaneously.

Stress and Cortisol Reduction

The clinical evidence supporting Rhodiola rosea's capacity to reduce stress and normalize cortisol levels is among the most robust in the adaptogen literature. Multiple randomized controlled trials have demonstrated that standardized Rhodiola extracts significantly alleviate subjective symptoms of stress while simultaneously modulating the biochemical markers of the stress response. These findings have established Rhodiola as a front-line botanical intervention for stress management in integrative medicine.

One of the most significant clinical studies examined 118 individuals suffering from stress-related burnout who received 400 mg of Rhodiola rosea daily for 12 weeks. Participants showed clear and statistically significant improvements in multiple symptoms commonly associated with burnout, including perceived stress, fatigue, depression, and cognitive dysfunction. Notably, the most pronounced improvements were observed during the first week of supplementation and continued to increase throughout the study period, suggesting both rapid onset of action and sustained cumulative benefits. This finding is particularly significant because it indicates that Rhodiola may offer faster symptomatic relief than many conventional interventions for stress-related conditions.

In animal models, chronic administration of Rhodiola rosea root powder has been shown to strongly reduce anxiety and corticosterone levels (the rodent equivalent of cortisol) induced by chronic stress protocols. These preclinical findings align with the clinical data and provide mechanistic support for the herb's stress-protective effects. The cortisol-modulating properties of Rhodiola are particularly noteworthy because they appear to be bidirectional -- the herb reduces cortisol when it is pathologically elevated by chronic stress while preserving the normal acute cortisol response necessary for healthy physiological function. This normalizing quality is the hallmark of a true adaptogen.

A comprehensive review published in Molecules (2022) analyzed the totality of clinical evidence for Rhodiola rosea preparations in alleviating life-stress symptoms and stress-induced conditions. The review concluded that the existing clinical evidence is encouraging and supports the traditional use of Rhodiola as an adaptogen for temporary stress relief. The reviewers noted that Rhodiola preparations demonstrated a consistent pattern of benefits across multiple stress-related outcomes, including reductions in perceived stress, improvements in energy and vitality, enhanced emotional stability, and improved quality of life measures.

Mental Performance and Cognitive Function

The effects of Rhodiola rosea on mental performance and cognitive function have been extensively investigated, with the majority of clinical studies focusing on its capacity to maintain or enhance cognitive abilities under conditions of stress, fatigue, and sleep deprivation. The herb's traditional reputation as a mental tonic capable of sharpening thought and improving concentration has been partially validated by modern research, though the evidence remains mixed and continues to evolve.

A landmark study investigated the effect of chronic administration of 170 mg of standardized Rhodiola rosea extract (SHR-5) on mental performance in 56 healthy physicians working night shifts. This randomized, double-blind, placebo-controlled, crossover trial measured cognitive function through a composite Fatigue Index reflecting complex perceptive and cognitive cerebral functions, including short-term memory, associative thinking, calculation speed, concentration, and audio-visual perception. The Rhodiola-treated group demonstrated statistically significant improvements in the Fatigue Index compared to placebo over a 14-day treatment period, establishing that the herb can preserve cognitive function under conditions of professional stress and sleep deprivation.

Another study involving 161 military cadets aged 19-21 examined the effects of a single dose of Rhodiola rosea extract on cognitive function during a period of fatigue and stress. Cadets who received Rhodiola showed significant improvements in capacity for mental work, as assessed by an Anti-Fatigue Index derived from multiple psychometric tests. Researchers also observed improvements in associative thinking, short-term memory, calculation, and speed of audiovisual perception. These findings suggest that even acute administration of Rhodiola can enhance cognitive performance under demanding conditions.

The mechanisms underlying Rhodiola's cognitive effects are believed to involve modulation of key neurotransmitter systems. Preclinical research has demonstrated that Rhodiola rosea extracts can increase levels of serotonin, dopamine, and norepinephrine in the central nervous system, neurotransmitters critically involved in attention, memory consolidation, and executive function. Salidroside and rosavin have also been shown to potentiate electrical stimulation in hippocampal circuits -- the brain region most centrally involved in learning and memory formation -- suggesting direct effects on synaptic plasticity. However, it is important to note that some well-designed studies have found no significant cognitive improvements, including a randomized controlled trial in male students that observed no enhancement in cognitive scores after 20 days of supplementation. These mixed results highlight the need for larger, more rigorous trials to define the conditions under which Rhodiola most reliably enhances cognitive performance.

Physical Endurance and Athletic Performance

Rhodiola rosea has attracted considerable attention as a potential ergogenic aid -- a substance that enhances physical performance, endurance, and recovery. This interest is rooted in the herb's long history of use by Viking warriors, Sherpa mountaineers, Soviet Olympic athletes, and Russian military personnel, all of whom reportedly used Rhodiola preparations to improve physical stamina under demanding conditions. Modern research has begun to systematically evaluate these traditional claims through controlled clinical trials and mechanistic studies.

A systematic review published in Frontiers in Nutrition (2022) analyzed the totality of evidence from studies examining Rhodiola rosea supplementation and exercise performance. The review found that most studies reported positive effects on athletic ability and sports performance, with no obvious adverse reactions. Specific outcomes included improvements in VO2max (maximal oxygen consumption, the gold standard measure of aerobic fitness), time to exhaustion, and time trial performance. Subjects who received acute Rhodiola supplementation completed time trials significantly faster compared to placebo, and the herb appeared to improve endurance performance partly by decreasing the perception of effort during submaximal exercise.

The ergogenic mechanisms of Rhodiola rosea are multifaceted. Research has identified several physiological pathways through which the herb may enhance physical performance: modulation of energy substrate stores and utilization, including enhanced glycogen synthesis and improved fatty acid mobilization; reductions in exercise-induced muscle damage, as evidenced by lower post-exercise creatine kinase levels; enhanced antioxidant capacity, with increases in total antioxidant capacity and superoxide dismutase alongside reductions in malondialdehyde (a marker of oxidative stress); and reduced lactate accumulation, indicating improved metabolic efficiency during exercise. Additionally, acute Rhodiola supplementation has been shown to decrease heart rate response during submaximal exercise, suggesting improved cardiovascular efficiency.

Current evidence suggests that acute supplementation (approximately 200 mg of standardized extract containing 3% rosavins and 1% salidroside, taken 60 minutes before exercise) may be more effective than chronic supplementation for improving endurance performance. A meta-analysis of endurance-related outcomes concluded that acute Rhodiola intake can prolong time-to-exhaustion and improve time trial performance in recreationally active males and females. However, the evidence for benefits from chronic supplementation (daily use over weeks or months) remains limited and inconclusive, suggesting that the herb's ergogenic effects may be most pronounced when used strategically around training sessions or competitions.

Anti-Fatigue Effects

The anti-fatigue properties of Rhodiola rosea are among its most consistently documented therapeutic effects and represent a primary reason for the herb's traditional use across multiple cultures. Fatigue -- whether physical, mental, or a combination of both -- is one of the most common complaints in modern society and is a hallmark symptom of chronic stress, burnout, and numerous medical conditions. Rhodiola rosea addresses fatigue through multiple complementary mechanisms, targeting both the central (neurological) and peripheral (metabolic and muscular) components of fatigue.

Clinical trials have repeatedly demonstrated that Rhodiola rosea extracts exert significant anti-fatigue effects that increase mental performance, particularly the ability to concentrate, in healthy subjects under stressful conditions. The standardized extract SHR-5 has been the most extensively studied preparation in this context. In the physician night-shift study described earlier, Rhodiola significantly reduced fatigue-induced impairment of cognitive function, allowing doctors to maintain higher levels of mental acuity during demanding overnight shifts. Similar results were observed in studies of students during examination periods, where Rhodiola supplementation helped preserve cognitive performance, physical fitness, and general well-being under conditions of intense academic stress and sleep restriction.

A systematic review specifically examining Rhodiola rosea for physical and mental fatigue, published in BMC Complementary and Alternative Medicine (2012), analyzed the evidence from 11 randomized controlled trials. While the reviewers noted methodological limitations in some studies, 10 of the 11 included trials reported beneficial effects on at least some fatigue-related outcomes. The review concluded that although more rigorous research is needed, the existing evidence suggests that Rhodiola may be helpful for alleviating both physical and mental fatigue, with a favorable safety profile that distinguishes it from pharmaceutical stimulants.

At the molecular level, Rhodiola's anti-fatigue effects are mediated through several interconnected pathways. The herb enhances cellular energy metabolism by supporting mitochondrial function and optimizing the synthesis and resynthesis of adenosine triphosphate (ATP), the body's primary energy currency. Rhodiola also modulates the activity of AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis, and reduces the accumulation of metabolic byproducts associated with fatigue, including lactate and ammonia. By simultaneously supporting energy production and reducing the biochemical burden of fatigue, Rhodiola provides a balanced anti-fatigue effect that does not rely on the stimulatory mechanisms employed by caffeine and other conventional stimulants -- and therefore avoids the characteristic "crash" associated with those substances.

Depression and Mood Support

The antidepressant potential of Rhodiola rosea has emerged as one of the most clinically significant areas of research on this adaptogen. Depression affects more than 280 million people worldwide, and many patients either do not respond adequately to conventional antidepressant medications or experience intolerable side effects. Rhodiola rosea has shown promise as both a standalone treatment for mild-to-moderate depression and as an adjunctive therapy that may enhance the efficacy of conventional antidepressants while mitigating their side effects.

The clinical evidence base for Rhodiola's antidepressant effects includes two randomized, double-blind, placebo-controlled trials involving a total of 146 subjects with major depressive disorder, as well as seven open-label studies totaling 714 individuals with stress-induced mild depression. The overall results from these trials suggest a possible antidepressant action, with significant improvements observed on standardized depression rating scales including the Hamilton Depression Rating Scale (HAM-D) and the Beck Depression Inventory (BDI). One study demonstrated that Rhodiola Capsule possesses clear and significant antidepressive activity in patients suffering from mild-to-moderate depression.

A particularly noteworthy clinical trial examined the combination of Rhodiola rosea (300 mg and 600 mg daily) with the selective serotonin reuptake inhibitor (SSRI) sertraline over 12 weeks in patients with major depressive disorder. The combination treatment showed no adverse effects and actually improved quality of life and clinical symptoms compared to sertraline alone. This finding is significant because it suggests that Rhodiola may serve as a safe and effective adjunctive treatment that enhances the therapeutic effects of conventional antidepressants. The study also highlights the favorable safety profile of Rhodiola when used alongside pharmaceutical medications.

The antidepressant mechanisms of Rhodiola rosea are believed to involve modulation of multiple neurotransmitter systems. Both salidroside and rosavin have been studied as potential compounds responsible for the herb's antidepressant actions. Preclinical evidence indicates that Rhodiola extracts increase the availability of serotonin, dopamine, and norepinephrine in the brain by inhibiting the enzymes monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), as well as catechol-O-methyltransferase (COMT) -- the same enzymatic targets addressed by some pharmaceutical antidepressants. Additionally, Rhodiola modulates beta-endorphin levels and opioid neuropeptides, which may contribute to its mood-elevating effects. In contrast to most conventional antidepressants, Rhodiola extract appears to be well-tolerated in short-term studies with a favorable safety profile, making it a particularly attractive option for patients who are sensitive to pharmaceutical side effects.

Anxiety Relief

In addition to its antidepressant properties, Rhodiola rosea has demonstrated clinically meaningful anxiolytic (anxiety-reducing) effects in both preclinical models and human clinical trials. Given the high comorbidity between anxiety disorders and depression, and the fact that chronic stress is a major precipitating factor for both conditions, Rhodiola's dual action on mood and anxiety makes it a particularly versatile botanical intervention for stress-related psychological disturbances.

A pilot study published in the Journal of Alternative and Complementary Medicine (2008) specifically investigated Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). Participants who received Rhodiola demonstrated significant improvements in GAD symptoms, with reductions in Hamilton Anxiety Rating Scale (HARS) scores comparable to those typically observed in clinical trials of pharmaceutical anxiolytics. Although the study was limited by its small sample size and open-label design, the results were sufficiently encouraging to warrant further investigation in larger, placebo-controlled trials.

A double-blind, placebo-controlled study involving 80 mildly anxious participants provided further evidence for Rhodiola's anxiolytic potential. The experimental group, which received Rhodiola rosea extract, demonstrated significant reductions in self-reported anxiety, stress, anger, confusion, and depression at 14 days compared to baseline and placebo. The study also reported significant improvements in total mood disturbance, suggesting that Rhodiola exerts broad beneficial effects on emotional well-being rather than targeting anxiety in isolation.

The anxiolytic mechanisms of Rhodiola rosea are thought to involve several complementary pathways. By modulating the HPA axis and reducing excessive cortisol secretion, Rhodiola addresses the neuroendocrine basis of anxiety. Its effects on the GABAergic system -- the brain's primary inhibitory neurotransmitter network -- may also contribute to its calming properties. Furthermore, Rhodiola's capacity to increase serotonin availability in the central nervous system is relevant because serotonin dysregulation is a central feature of anxiety disorders and the primary target of SSRI medications. The herb's favorable safety profile and lack of sedating effects distinguish it from conventional anxiolytics such as benzodiazepines, which carry significant risks of dependence, tolerance, and cognitive impairment.

Immune System Modulation

Rhodiola rosea exhibits significant immunomodulatory properties, meaning it can influence the activity and regulation of the immune system in ways that promote balanced immune function rather than simply stimulating or suppressing immunity. This balanced approach to immune regulation is consistent with the herb's broader adaptogenic profile and distinguishes it from simple immunostimulants. Modern pharmacological research has revealed that Rhodiola and its constituent compounds exert immune-regulating effects through multiple inflammatory mediators and signaling pathways.

Preclinical studies have demonstrated that Rhodiola rosea extracts can enhance several components of innate immunity, including natural killer (NK) cell activity, macrophage phagocytic function, and the production of key immune-signaling cytokines. At the same time, Rhodiola appears to modulate the adaptive immune response by influencing T-lymphocyte proliferation and differentiation. These dual effects on innate and adaptive immunity suggest that Rhodiola can help the immune system respond more effectively to infections and other challenges while reducing the risk of excessive or misdirected immune activation.

The immunomodulatory effects of Rhodiola are mediated through several key molecular pathways. Research has identified that Rhodiola and its compounds influence immune regulation through signaling cascades including NF-kB, AP-1 (activator protein 1), and STAT3 (signal transducer and activator of transcription 3). These transcription factors play central roles in determining the magnitude and character of the immune response, and their modulation by Rhodiola constituents helps explain the herb's ability to fine-tune immune function. Salidroside, in particular, has been shown to counteract inflammation through inhibition of the P2X7/NF-kB/NLRP3 inflammasome pathway, a signaling axis critically involved in the production of pro-inflammatory cytokines such as interleukin-1 beta (IL-1beta).

The connection between stress and immune function adds another dimension to Rhodiola's immunomodulatory value. Chronic psychological stress is a well-established suppressor of immune function, acting through sustained cortisol elevation and sympathetic nervous system activation to impair immune surveillance and increase susceptibility to infections. By normalizing the stress response and reducing excessive cortisol secretion, Rhodiola may indirectly support immune function by removing one of the most significant barriers to optimal immune performance. This dual mechanism -- direct immunomodulation combined with stress-mediated immune support -- positions Rhodiola as a particularly comprehensive botanical approach to maintaining immune health during periods of high stress.

Anti-Inflammatory Properties

Rhodiola rosea has been confirmed to possess significant protective effects against inflammatory injury across a wide range of disease models. The herb's anti-inflammatory properties are mediated through multiple complementary mechanisms that target key nodes in the inflammatory signaling network, making it a broad-spectrum botanical anti-inflammatory agent. These properties are particularly relevant given that chronic, low-grade inflammation (sometimes called "inflammaging") is now recognized as a common underlying factor in many of the most prevalent chronic diseases, including cardiovascular disease, neurodegenerative conditions, diabetes, and cancer.

Research has demonstrated that Rhodiola rosea extracts and their constituent compounds modulate multiple pro-inflammatory mediators and signaling cascades. Specifically, Rhodiola has been shown to reduce the production and activity of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1 beta (IL-1beta), and cyclooxygenase-2 (COX-2) -- all central mediators of the inflammatory response. At the transcriptional level, Rhodiola suppresses the activation of nuclear factor kappa B (NF-kB), the master transcription factor that controls the expression of hundreds of pro-inflammatory genes. By inhibiting NF-kB activation, Rhodiola simultaneously reduces the production of multiple inflammatory mediators, providing a more comprehensive anti-inflammatory effect than agents that target only a single inflammatory pathway.

Salidroside has emerged as the primary anti-inflammatory compound in Rhodiola rosea. In vitro and in vivo studies have demonstrated that salidroside exerts its anti-inflammatory effects through suppression of the NF-kB pathway, inhibition of the PI3K/AKT signaling cascade, and activation of the Nrf2/HO-1 antioxidant defense pathway. The Nrf2/HO-1 pathway is particularly important because it represents a point of convergence between antioxidant defense and anti-inflammatory regulation -- activation of Nrf2 simultaneously enhances antioxidant enzyme production and suppresses pro-inflammatory gene expression, creating a powerful dual mechanism of cellular protection.

The anti-inflammatory effects of Rhodiola rosea have been documented in preclinical models of numerous disease states, including cardiovascular disease, neurodegenerative disorders, diabetes, sepsis, and cancer. A comprehensive review published in Biomedicine and Pharmacotherapy (2019) concluded that Rhodiola's protective effects against inflammatory injury have been confirmed across multiple organ systems and disease models, supporting its potential as a therapeutic agent for conditions characterized by excessive or chronic inflammation. These findings align with the traditional use of Rhodiola in treating inflammatory conditions and provide a mechanistic basis for its broad therapeutic applicability.

Cardiovascular Benefits

Rhodiola rosea has demonstrated significant cardiovascular protective effects in both preclinical research and limited clinical studies. The herb's cardioprotective properties encompass multiple mechanisms that collectively support heart health, improve vascular function, and protect the cardiovascular system from stress-induced damage. Given that cardiovascular disease remains the leading cause of death worldwide, the potential of Rhodiola rosea as a cardioprotective botanical agent is of considerable clinical interest.

The cardioprotective effects of Rhodiola rosea include the prevention of stress-induced cardiac damage, decreased levels of myocardial catecholamines (epinephrine and norepinephrine in heart tissue), reduced cyclic adenosine monophosphate (cAMP) levels in the myocardium, and decreased adrenal catecholamine release. These effects are particularly significant because excessive catecholamine stimulation of the heart -- a hallmark of chronic stress -- is a well-established mechanism of stress-induced cardiac injury, arrhythmia, and cardiomyopathy. By moderating catecholamine levels and their cardiac effects, Rhodiola provides a specific mechanism of protection against stress-related heart damage.

Preclinical research on Rhodiola rosea for ischemic stroke -- a condition caused by interrupted blood flow to the brain -- has yielded encouraging results. A systematic review and meta-analysis of preclinical evidence found that Rhodiola rosea and its components demonstrated significant neuroprotective and cardioprotective effects in ischemic models, reducing infarct size, improving neurological deficit scores, and decreasing markers of oxidative stress and inflammation. These protective effects were attributed primarily to salidroside and involved the suppression of oxidative damage, the reduction of inflammatory cascades, and the inhibition of apoptosis (programmed cell death) in ischemic tissues.

Additionally, Rhodiola rosea has been shown to exert beneficial effects on lipid metabolism, with rosavin demonstrating lipid-lowering properties that may contribute to the prevention of atherosclerosis. The herb's antioxidant properties help prevent the oxidation of low-density lipoprotein (LDL) cholesterol -- a critical early step in the development of atherosclerotic plaques. The combined effects of stress reduction, catecholamine modulation, anti-inflammatory action, lipid regulation, and antioxidant protection establish Rhodiola rosea as a multifaceted botanical agent for cardiovascular support, particularly in the context of stress-related cardiovascular risk.

Neuroprotective Effects

The neuroprotective properties of Rhodiola rosea have attracted increasing scientific attention as the burden of neurodegenerative diseases continues to grow worldwide. Research has revealed that Rhodiola and its constituent compounds possess multiple mechanisms of neuronal protection that may be relevant to conditions such as Alzheimer's disease, Parkinson's disease, cerebral ischemia, and age-related cognitive decline. The neuroprotective activity of Rhodiola is primarily attributed to salidroside, though other compounds in the extract also contribute to these effects.

The neuroprotective activity of salidroside operates through several key molecular mechanisms. Foremost among these is the reduction of oxidative stress through enhanced expression of antioxidant enzymes and activation of the Nrf2/HO-1 pathway. The brain is particularly vulnerable to oxidative damage due to its high metabolic rate, high lipid content, and relatively modest antioxidant defenses. By bolstering the brain's intrinsic antioxidant capacity, salidroside provides a foundational layer of neuronal protection. Additionally, salidroside has been shown to decrease neuroinflammation through suppression of the NF-kB pathway and modulation of microglial activation -- microglia being the brain's resident immune cells, whose excessive activation contributes to neuroinflammatory damage in multiple neurodegenerative conditions.

Research from 2025 on the comprehensive profiling of Rhodiola rosea roots demonstrated significant modulation of neuroinflammation in BV2 microglial cell models, providing direct evidence that Rhodiola constituents can regulate the neuroinflammatory processes implicated in neurodegenerative disease. The study showed that Rhodiola extracts reduced the production of pro-inflammatory mediators by activated microglia, suggesting a mechanism by which the herb may slow the progression of neuroinflammatory conditions. Furthermore, salidroside has demonstrated anti-apoptotic effects in neuronal cells, protecting against programmed cell death triggered by oxidative stress, excitotoxicity, and other neurotoxic insults.

The cognitive enhancement and memory-improving effects of Rhodiola discussed earlier are closely related to its neuroprotective properties. Preclinical evidence indicates that Rhodiola rosea improves learning and memory function through multiple mechanisms, including antioxidant activity, cholinergic regulation (modulation of acetylcholine, the neurotransmitter most critically involved in memory), anti-inflammatory actions, improved coronary blood flow, and enhanced cerebral metabolism. The herb's capacity to increase neurotransmitter levels, support central nervous system activity, and improve cardiovascular function all contribute to its neuroprotective profile. While most of the neuroprotective evidence comes from preclinical models, the consistent and mechanistically coherent findings across multiple studies support the potential of Rhodiola rosea as a neuroprotective botanical agent worthy of further clinical investigation.

Dosage and Standardization

The effective dosage of Rhodiola rosea varies depending on the specific therapeutic goal, the form of the preparation, and the standardization of the extract. Clinical trials have most commonly employed doses ranging from 100 to 600 mg per day of standardized extract, with most studies using treatment periods of 4 to 12 weeks. The appropriate dose depends on whether the herb is being used for acute performance enhancement, chronic stress management, mood support, or general adaptogenic maintenance.

The gold standard for Rhodiola rosea extract standardization is the 3:1 rosavin-to-salidroside ratio, which reflects the naturally occurring proportion of these compounds in high-quality root material. The most widely studied standardized extract, known as SHR-5, is calibrated to contain a minimum of 3% rosavins and 1% salidroside. This standardization ensures consistent potency and therapeutic reproducibility across different batches and manufacturers. Consumers and practitioners should verify that commercial Rhodiola products specify their rosavin and salidroside content, as unstandardized products may vary dramatically in their active compound concentrations and therefore in their clinical effectiveness.

For stress management and general adaptogenic support, the most commonly studied dose is 200-400 mg daily of a standardized extract (3% rosavins, 1% salidroside), taken in one or two divided doses. For cognitive enhancement and anti-fatigue effects, doses of 100-300 mg daily have shown benefit in clinical trials. For depression and mood support, doses of 300-600 mg daily have been used in clinical studies. For acute athletic performance enhancement, approximately 200 mg taken 60 minutes before exercise has shown the most consistent ergogenic effects.

Rhodiola rosea is generally recommended to be taken in the morning or early afternoon, as its mildly stimulating properties may interfere with sleep if taken too late in the day. Many practitioners recommend taking Rhodiola on an empty stomach for optimal absorption, approximately 20-30 minutes before meals. Some clinicians also suggest cycling Rhodiola use -- for example, taking it for five days followed by two days off, or using it for several weeks followed by a break -- to prevent tolerance development, though there is limited clinical evidence specifically supporting cycling protocols. Treatment durations in clinical trials have typically ranged from 6 to 12 weeks, which appears to be safe for most individuals based on the available evidence.

Forms and Preparations

Rhodiola rosea is commercially available in several different forms, each with distinct advantages regarding convenience, potency, absorption, and therapeutic application. Understanding the characteristics of each preparation can help consumers and practitioners select the most appropriate form for their specific needs and preferences.

Standardized capsules and tablets are the most common commercial form of Rhodiola rosea and the preparation most frequently used in clinical research. These products typically contain dry extracts standardized to 3% rosavins and 1% salidroside, providing consistent and reproducible doses of the key bioactive compounds. Capsules offer the advantages of precise dosing, portability, ease of use, and protection of the active compounds from degradation by light and moisture. Most clinical trials have used encapsulated standardized extracts, making this the form with the strongest evidence base.

Liquid extracts and tinctures offer an alternative delivery method that may provide faster absorption compared to capsules and tablets. Tinctures are prepared by extracting the dried root in alcohol (typically 40-60% ethanol), which effectively dissolves both water-soluble and alcohol-soluble bioactive compounds. Liquid preparations allow for more flexible dosing and may be preferred by individuals who have difficulty swallowing capsules. However, the alcohol content may be a concern for some users, and standardization of active compounds is often less precise in tincture form than in standardized dry extracts.

Rhodiola tea represents the most traditional form of preparation and can be made by simmering dried Rhodiola root pieces in hot water for 10-15 minutes. This was the primary preparation method used by the Vikings, Siberian villagers, and other traditional cultures. While tea provides a pleasant and ritualistic way to consume the herb, the concentration of active compounds is generally lower and more variable than in standardized extracts, making precise dosing difficult. Tea preparation also extracts primarily water-soluble compounds, potentially missing some of the alcohol-soluble bioactive constituents.

Powdered root is available for direct consumption, encapsulation, or incorporation into smoothies and other preparations. Whole root powder contains the full spectrum of the plant's phytochemicals in their natural proportions but is not standardized, meaning that the concentration of active compounds may vary significantly between batches and suppliers. Some practitioners prefer whole root powder for its completeness, arguing that the synergistic interaction of all native compounds produces superior therapeutic effects compared to standardized extracts. Salidroside-enriched extracts represent a newer category of Rhodiola preparations that contain higher-than-natural concentrations of salidroside (sometimes up to 10% or more), based on research suggesting that salidroside may be responsible for many of Rhodiola's most significant pharmacological effects. These concentrated preparations are increasingly popular in the nootropic and sports supplement communities.

Safety, Side Effects, and Contraindications

Rhodiola rosea has demonstrated an excellent safety profile across decades of traditional use and in modern clinical trials. The available evidence indicates that standardized Rhodiola extracts are well-tolerated at recommended doses, and no serious adverse events have been reported in controlled clinical studies. Taking rhodiola twice daily for 6 to 12 weeks appears to be safe for most adults based on the collective evidence from randomized controlled trials. According to the National Center for Complementary and Integrative Health (NCCIH), there is limited evidence on the safety of long-term use beyond 12 weeks.

The side effects that have been reported in clinical studies and post-market surveillance are generally mild and infrequent. The most commonly reported adverse effects include dizziness, dry mouth, excessive salivation (paradoxically), mild headache, restlessness, and insomnia (particularly when taken late in the day or at higher doses). Some users report a transient sensation of jitteriness or overstimulation when first starting Rhodiola, which typically resolves within a few days as the body adjusts. Gastrointestinal discomfort has been reported rarely. These side effects are generally dose-dependent and can often be managed by adjusting the timing or reducing the dose.

Several contraindications and precautions should be observed with Rhodiola rosea supplementation. The safety of Rhodiola in pregnant and breastfeeding women has not been established through clinical studies, and these populations should avoid the herb unless directed by a qualified healthcare provider. Similarly, the safety profile in children has not been specifically evaluated. Individuals with autoimmune disorders -- including multiple sclerosis, rheumatoid arthritis, lupus, and other autoimmune conditions -- should exercise caution, as Rhodiola may stimulate immune function and could theoretically worsen autoimmune disease activity. People with bipolar disorder should use Rhodiola with caution due to its potential to influence mood and neurotransmitter levels.

Because Rhodiola rosea has mild stimulating properties, individuals who are highly sensitive to stimulants or who suffer from anxiety disorders with prominent agitation should start with a low dose and monitor their response carefully. The herb should not be viewed as a replacement for professional medical treatment of serious mental health conditions, and individuals with moderate-to-severe depression or anxiety disorders should use Rhodiola only under the guidance of a qualified healthcare provider. As with all dietary supplements, quality and purity can vary significantly between manufacturers, and consumers should select products from reputable companies that provide third-party testing and transparent standardization information.

Drug Interactions

While Rhodiola rosea is generally considered safe, several potential drug interactions have been identified that warrant careful consideration by individuals taking pharmaceutical medications. These interactions arise from Rhodiola's pharmacological effects on neurotransmitter systems, blood pressure regulation, blood sugar metabolism, and hepatic enzyme activity. Patients taking prescription medications should consult with a healthcare provider before adding Rhodiola to their regimen.

Antidepressant medications: Rhodiola rosea may interact with antidepressant drugs, including SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), and tricyclic antidepressants. Because Rhodiola itself influences serotonin, dopamine, and norepinephrine metabolism, concurrent use with pharmaceutical antidepressants could theoretically potentiate serotonergic and catecholaminergic effects, potentially increasing the risk of side effects such as serotonin syndrome (characterized by agitation, confusion, rapid heart rate, and elevated blood pressure) or very rapid heart rate. While one clinical trial demonstrated the safety of combining Rhodiola with sertraline under controlled conditions, the general recommendation is to use Rhodiola cautiously alongside antidepressants and only under professional supervision.

Blood pressure medications: Rhodiola rosea may interact with antihypertensive drugs (medications that lower blood pressure). Because Rhodiola itself can influence blood pressure, concurrent use with pharmaceutical blood pressure-lowering agents may result in an additive hypotensive effect, potentially causing blood pressure to drop too low. Symptoms of excessive blood pressure reduction include dizziness, lightheadedness, fainting, and fatigue. Individuals taking ACE inhibitors, beta-blockers, calcium channel blockers, diuretics, or other antihypertensive medications should have their blood pressure monitored closely if they begin taking Rhodiola. Specific interactions have been reported between Rhodiola and losartan, an angiotensin receptor blocker commonly used to treat high blood pressure.

Diabetes medications: Rhodiola rosea may lower blood sugar levels, creating a potential interaction with insulin and oral hypoglycemic agents used to manage diabetes. Concurrent use could lead to hypoglycemia (blood sugar levels that are too low), which can cause symptoms ranging from shakiness and confusion to loss of consciousness in severe cases. Diabetic patients using Rhodiola should monitor their blood glucose levels more frequently and discuss dosage adjustments with their healthcare provider. Anticoagulant and antiplatelet medications: Rhodiola may affect the metabolism or activity of blood-thinning medications, including warfarin. Patients taking anticoagulants should have their coagulation parameters (INR/PT) monitored more closely if they begin Rhodiola supplementation. Sedative medications: Taking Rhodiola with sedative drugs, including benzodiazepines, barbiturates, and certain sleep aids, may alter the effects of these medications, potentially causing breathing problems or excessive sleepiness. Individuals taking any prescription medications should consult with a pharmacist or physician knowledgeable in herb-drug interactions before starting Rhodiola supplementation.

Synergistic Combinations

Rhodiola rosea is frequently combined with other adaptogenic herbs and complementary natural compounds to create formulations that target specific health goals more comprehensively than any single agent could achieve alone. The rationale for adaptogenic combinations is that different adaptogens influence different points along the stress-response pathway, and thoughtfully designed combinations are more likely to cover the full spectrum of neuroendocrine, immune, metabolic, and psychological stress responses, providing a more thorough and synergistic effect.

Rhodiola and Ashwagandha (Withania somnifera): This is perhaps the most popular adaptogenic pairing in modern herbal practice. The combination is based on the complementary pharmacological profiles of the two herbs -- Rhodiola is generally the more energizing and stimulating adaptogen, while Ashwagandha is typically more calming and grounding. Together, they may support calm focus, balanced mood, and steady energy without the excessive stimulation or sedation that either herb might produce alone at higher doses. Rhodiola modulates neurotransmitters (serotonin, dopamine) and helps balance cortisol release, supporting mental stamina and resilience, while Ashwagandha reduces overactivity of the HPA axis and lowers cortisol, particularly benefiting chronic stress and anxiety. However, because the two herbs have somewhat opposing effects on arousal, the combination may not be ideal for everyone, and individual responses should be monitored.

Rhodiola and Schisandra (Schisandra chinensis): This combination has deep roots in Soviet adaptogen research, where both herbs were studied extensively as performance-enhancing agents. Schisandra supports liver function, modulates stress-related metabolic pathways, and provides additional antioxidant protection. The combination of Rhodiola and Schisandra has been shown in animal studies to synergistically suppress increases in phosphorylated stress-activated protein kinase, nitric oxide, and cortisol in response to immobilization stress. Rhodiola and Eleuthero (Eleutherococcus senticosus): Known as Siberian ginseng, Eleuthero enhances adrenal function and stamina, supporting energy reserves through mechanisms that complement Rhodiola's effects on the HPA axis and neurotransmitter systems.

Rhodiola and L-Theanine: L-Theanine, an amino acid found primarily in green tea, increases levels of calming neurotransmitters including GABA and serotonin while reducing neuronal excitability. When combined with Rhodiola, L-Theanine may help moderate the herb's mildly stimulating effects while enhancing its cognitive benefits, producing a state of alert relaxation that is ideal for focused mental work. Rhodiola and Magnesium: Magnesium is an essential mineral involved in over 300 enzymatic reactions, including those critical for nervous system function, muscle relaxation, and energy metabolism. Combining Rhodiola with magnesium may provide complementary support for stress management, with Rhodiola addressing the neuroendocrine stress response while magnesium supports the biochemical and muscular dimensions of stress recovery. Rhodiola and Holy Basil (Ocimum tenuiflorum): Holy Basil, another well-researched adaptogen, provides additional anti-inflammatory and anxiolytic support that complements Rhodiola's adaptogenic and cognitive-enhancing properties.

References and Further Reading

  1. Panossian, A., Wikman, G., and Sarris, J. "Rosenroot (Rhodiola rosea): Traditional Use, Chemical Composition, Pharmacology and Clinical Efficacy." Phytomedicine, vol. 17, no. 7, 2010, pp. 481-493.
  2. Ishaque, S., Shamseer, L., Bukutu, C., and Vohra, S. "Rhodiola rosea for Physical and Mental Fatigue: A Systematic Review." BMC Complementary and Alternative Medicine, vol. 12, 2012, Article 70.
  3. Anghelescu, I.G., Edwards, D., Seifritz, E., and Kasper, S. "Stress Management and the Role of Rhodiola rosea: A Review." International Journal of Psychiatry in Clinical Practice, vol. 22, no. 4, 2018, pp. 242-252.
  4. Cropley, M., Banks, A.P., and Boyle, J. "The Effects of Rhodiola rosea L. Extract on Anxiety, Stress, Cognition and Other Mood Symptoms." Phytotherapy Research, vol. 29, no. 12, 2015, pp. 1934-1939.
  5. Darbinyan, V., Kteyan, A., Panossian, A., et al. "Rhodiola rosea in Stress Induced Fatigue -- A Double Blind Cross-Over Study of a Standardized Extract SHR-5 with a Repeated Low-Dose Regimen on the Mental Performance of Healthy Physicians During Night Duty." Phytomedicine, vol. 7, no. 5, 2000, pp. 365-371.
  6. Mao, J.J., Xie, S.X., Zee, J., et al. "Rhodiola rosea versus Sertraline for Major Depressive Disorder: A Randomized Placebo-Controlled Trial." Phytomedicine, vol. 22, no. 3, 2015, pp. 394-399.
  7. Bystritsky, A., Kerwin, L., and Feusner, J.D. "A Pilot Study of Rhodiola rosea (Rhodax) for Generalized Anxiety Disorder (GAD)." Journal of Alternative and Complementary Medicine, vol. 14, no. 2, 2008, pp. 175-180.
  8. Lu, Y., Deng, B., Xu, L., et al. "Effects of Rhodiola Rosea Supplementation on Exercise and Sport: A Systematic Review." Frontiers in Nutrition, vol. 9, 2022, Article 856287.
  9. De Bock, K., Eijnde, B.O., Ramaekers, M., and Hespel, P. "Acute Rhodiola rosea Intake Can Improve Endurance Exercise Capacity." International Journal of Sport Nutrition and Exercise Metabolism, vol. 14, no. 3, 2004, pp. 298-307.
  10. Li, Y., Pham, V., Bui, M., et al. "Rhodiola rosea L.: An Herb with Anti-Stress, Anti-Aging, and Immunostimulating Properties for Cancer Chemoprevention." Current Pharmacology Reports, vol. 3, 2017, pp. 384-395.
  11. Recio, M.C., Giner, R.M., and Manez, S. "Anti-inflammatory Effects of Rhodiola rosea L.: A Review." Biomedicine and Pharmacotherapy, vol. 121, 2020, Article 109552.
  12. Tao, H., Wu, X., Cao, J., et al. "Rhodiola Species: A Comprehensive Review of Traditional Use, Phytochemistry, Pharmacology, Toxicity, and Clinical Study." Medicinal Research Reviews, vol. 39, no. 5, 2019, pp. 1779-1850.
  13. Amsterdam, J.D. and Panossian, A.G. "Rhodiola rosea L. as a Putative Botanical Antidepressant." Phytomedicine, vol. 23, no. 7, 2016, pp. 770-783.
  14. Panossian, A., Hambardzumyan, M., Hovhannisyan, A., and Wikman, G. "The Adaptogens Rhodiola and Schizandra Modify the Response to Immobilization Stress in Rabbits by Suppressing the Increase of Phosphorylated Stress-Activated Protein Kinase, Nitric Oxide and Cortisol." Drug Target Insights, vol. 2, 2007, pp. 39-54.
  15. Ma, G.P., Zheng, Q., Xu, M.B., et al. "Rhodiola rosea L. Improves Learning and Memory Function: Preclinical Evidence and Possible Mechanisms." Frontiers in Pharmacology, vol. 9, 2018, Article 1415.
  16. Kasper, S. and Dienel, A. "Multicenter, Open-Label, Exploratory Clinical Trial with Rhodiola rosea Extract in Patients Suffering from Burnout Symptoms." Neuropsychiatric Disease and Treatment, vol. 13, 2017, pp. 889-898.
  17. Zheng, T., Bian, F., Chen, L., et al. "Beneficial Effects of Rhodiola and Salidroside in Diabetes: Potential Role of AMP-Activated Protein Kinase." International Journal of Molecular Sciences, vol. 20, no. 11, 2019, Article 2796.
  18. European Medicines Agency. "Community Herbal Monograph on Rhodiola rosea L., Rhizoma et Radix." EMA/HMPC/232091/2011, 2012.
  19. Lucius, K. "Rhodiola rosea: Clinical Evidence for Adaptogenic and Ergogenic Effects." Integrative and Complementary Therapies, 2024.
  20. Gao, J., He, H., Jiang, W., et al. "Salidroside Ameliorates Cognitive Impairment in a D-Galactose-Induced Rat Model of Alzheimer's Disease." Behavioural Brain Research, vol. 293, 2015, pp. 27-33.

Back to Table of Contents